secwatch.observer — SEC 8-K summary
======================================

Issuer:     Immunovant, Inc. (IMVT)
CIK:        0001764013
Form:       8-K
Filed at:   2025-11-10T23:59:59+00:00
Accession:  0001764013-25-000148
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Immunovant Q2 loss $126.5M; batoclimab TED readout delayed to H1 2026; cash $521.9M
--------------------------------------------------------------------------------

- Net loss $126.5M ($0.73/share) in fiscal Q2 ended Sep 30, 2025, vs $109.1M ($0.74) prior year.
- Cash and equivalents $521.9M providing runway through GD readout expected in 2027.
- Batoclimab Phase 3 TED: first readout delayed; both studies now expected to report concurrently H1 2026.
- IMVT-1402 GD study showed first-ever potentially disease-modifying therapy with 6-month off-treatment data.
- Topline results for IMVT-1402 in D2T RA and CLE expected 2026; GD, MG, D2T RA in 2027.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1764013/000176401325000148/0001764013-25-000148-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1764013/000176401325000148/imvt-20251110.htm
  HTML page:      https://secwatch.observer/filing/0001764013-25-000148

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer